The stock will trade on pipeline execution, not Q2 financials. The key near-term catalyst is the STX-1150 Phase 1 data readout in H1 2027. Monitor for any early safety/efficacy signals from the SAD portion. The IPO removes near-term financing overhang, but the company remains pre-revenue and clinical-stage.
Price Chart
Executive Summary
Scribe Therapeutics reported Q2 2026 results: net loss of $6.5M ($2.62/share) vs. $9.9M loss ($4.08/share) a year ago, on collaboration revenue of $1.9M (down from $4.9M). The quarter was overshadowed by the transformative July IPO and concurrent Sanofi private placement raising ~$155.5M, extending cash runway into H1 2029. The key catalyst is the initiation of the Phase 1 trial for lead asset STX-1150 (LDL-C lowering), with initial clinical data expected in H1 2027, alongside CIRM grants for STX-1200 and STX-1400.
Key Financial Metrics
Key Facts
- Initiated first-in-human Phase 1 trial of STX-1150 (epigenetic PCSK9 silencer) in Australia; initial clinical data expected H1 2027.
- Awarded ~$25.7M in non-dilutive CIRM grants for STX-1200 (Lp(a)) and STX-1400 (triglycerides).
- Completed upsized IPO and concurrent Sanofi private placement, generating ~$155.5M in gross proceeds.
- Cash, cash equivalents, and marketable securities were $43.0M as of June 30, 2026; plus ~$140.6M net IPO proceeds provides funding into H1 2029.
- Net loss narrowed to $6.5M ($2.62/share) for Q2 2026 from $9.9M ($4.08/share) in Q2 2025.
- Collaboration revenue fell to $1.9M from $4.9M YoY due to lower reimbursable R&D activities.
Financial Impact
Net loss of $6.5M on $1.9M revenue; cash position of $43.0M plus ~$140.6M net IPO proceeds extends runway into H1 2029.
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; STX-1150 Phase 1 data is binary and not expected until H1 2027.
- Collaboration revenue declined 61% YoY; reliance on partnership funding.
- Significant stockholder deficit of $164.8M as of June 30, 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-380184 |
| Document: sctx-20260902.htm | 0001193125-26-380184 |
| Document: 0001193125-26-380184-index-headers.html | 0001193125-26-380184 |
| Document: 0001193125-26-380184-index.html | 0001193125-26-380184 |
| Document: 0001193125-26-380184.txt | 0001193125-26-380184 |
| 8-K Data (Synthetic) | 0001193125-26-380184 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 8-K | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.60 (−49.37%) |
Sep 2, 2026 7w ago | Press Release | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.60 (−49.37%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.60 (−23.53%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.60 (−23.53%) |
Jul 28, 2026 12w ago | Insider Cluster | $18.36 $31.70 | ▲ +72.66% | ▲ +67.64% | $15.60 (−15.03%) |
Jul 24, 2026 13w ago | 424B4 | $18.97 $37.25 | ▲ +96.36% | ▲ +93.06% | $15.60 (−17.76%) |
Jul 24, 2026 13w ago | EFFECT | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.60 (−27.94%) |
Jul 23, 2026 13w ago | 3 / PRESS-RELEASE | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.60 (−27.94%) |
Jul 20, 2026 14w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers